News
Rona Therapeutics said Roche took an exclusive worldwide license to its ALK7-targeting RNAi candidate for obesity, with up to $100 million in upfront and near-term payments.
Aspect Biosystems plans clinical data in 2027 from cell therapy pipeline, CEO says at Meeting on the Mesa
Sartorius says one operator can run eight cell therapy patients on Eveo platform at Meeting on the Mesa
CGT Catapult pitches ‘federation’ to lower cell and gene therapy development costs at Meeting on the Mesa
BOOST Pharma outlines placebo-controlled trial of up to 80 patients for brittle bone cell therapy BT-101 at Meeting on the Mesa
Tamer Mohamed told Cell & Gene Meeting on the Mesa that Aspect Biosystems plans to generate clinical data in 2027, and set out preclinical data for its adrenal insufficiency and type 1 diabetes programs.
Published 7 Oct 2026
Sartorius chief technology officer Oscar-Werner Reif told the Cell & Gene Meeting on the Mesa the company believes its automated Eveo platform can bring cell therapy costs below $40,000 per patient.
Published 7 Oct 2026
Stephen Ward, chief technology officer of the UK’s Cell and Gene Therapy Catapult, told Meeting on the Mesa that developers can share data, testbeds and manufacturing space without losing control.
Published 7 Oct 2026
CEO Hans Schambye told Cell & Gene Meeting on the Mesa that BOOST Pharma expects to be able to start a placebo-controlled trial of BT-101, its investigational stem cell therapy for osteogenesis imperfecta, in the middle of next year.
Published 7 Oct 2026
Tim Hunt told Cell & Gene Meeting on the Mesa that Wall Street data point to seven more cell and gene therapy blockbusters, and said ARM will soon announce changes to its membership dues.
Published 6 Oct 2026
Karim Mikhail told Cell & Gene Meeting on the Mesa the FDA wants eventually to bring its separate rare disease efforts into one package, and set out how the Expedited IND Pilot is meant to speed up first-in-human trials.
Published 6 Oct 2026
Deal brings Exl-111 into Novartis’s allergy portfolio, targeting IgE-driven diseases including food allergy and asthma.
Sanofi will obtain exclusive worldwide rights to Kali Therapeutics’ KT501 under an agreement covering a tri-specific T-cell engager for B cell-mediated autoimmune diseases.
Lupin gained semi-exclusive rights to co-market Zydus’ semaglutide injection in India, while Sun Pharma launched Noveltreat and Sematrinity for chronic weight management and type 2 diabetes.
Rhythm Pharmaceuticals said the FDA approved IMCIVREE for acquired hypothalamic obesity, making it the first FDA-approved therapy for the condition.
The deal increases Abbott’s exposure to a U.S. cancer screening and precision oncology diagnostics market the company sizes at $60 billion.
The FDA issued a Complete Response Letter for Aldeyra’s reproxalap application in dry eye disease, citing insufficient evidence of efficacy and inconsistent trial results.
The FDA approval extends Cosentyx into pediatric hidradenitis suppurativa, with use supported by adult studies, pharmacokinetic modeling, and pediatric data from other approved indications
The approved NEO system is designed to restore hand-grasping ability through neural signal decoding and a robotic glove.
Eli Lilly said testing found an impurity in compounded tirzepatide products mixed with vitamin B12 and urged FDA action.
SUCCESSOR-2 is mezigdomide’s first positive Phase 3 study and the CELMoD program’s second. The trial showed a progression-free survival benefit over carfilzomib and dexamethasone alone.
BioNTech said its pipeline and COVID-19 vaccine franchise remain unaffected as its co-founders prepare to move to a new independent mRNA company.
Vertex reported positive Week 36 interim Phase 3 data for povetacicept in IgAN and said it will complete its BLA by the end of March.
Inside the next breakthrough.
The Vancouver immunologist on myeloid cells as a delivery route, STING for cold tumours, and why in vivo CAR could land near the price of a checkpoint inhibitor.
The Cambridge founder on re-engineering antibodies to break into solid tumours, raising a seed round without a professor behind her, and why hiring in the UK is her hardest problem.
CamMed CEO Dr. Ahmet Can Berkyurek on an AI-discovered, single-protein replicase drawn from biology's most ancient machinery — and his case for building it in the UK
CEO Rob Etherington and chief scientist Mark Mortenson on the bioenergetic thesis behind CNM-Au8, the HEALEY data, and five meetings with the agency.
Pierre Fabre / Atara
Tabelecleucel (Ebvallo)
EBV+ Post-Transplant Lymphoproliferative Disease
Aquestive Therapeutics
Anaphylm (dibutepinephrine)
Anaphylaxis
REGENXBIO
RGX-121 (clemidsogene)
Hunter Syndrome (MPS II)
Aldeyra Therapeutics
Reproxalap
Dry Eye Disease
Vanda Pharmaceuticals
Tradipitant
Gastroparesis
TLDRBiotech(too long, didn't read)
Anis Fahandej-SadiHead Editor, TLDR Biotech
The top stories in biotech & pharma, straight to your inbox in only one email.The good, the bad and the ugly.
SubscribeOnyx, in your corner
Follow the people, science and decisions shaping biotech. Explore Onyx membership.
Already a member? Sign in
